PLATFORM

(TECHNOLOGY)

PIN™ PLATFORM PROVIDES A UNIQUE CAPABILITY TO TARGET COMPLEX AND CHALLENGING PATHOLOGIES

EFFECTOR CELLS

TARGETING LIGANDS

FOR ANY GIVEN TARGET AND INDICATION

(NK CELLS)

(MACROPHAGES)

(OTHER CELLS)

(ANTIBODIES)

(LIGANDS)

(HEMATOLOGY)

(SOLID TUMOR)

(AUTOIMMUNE DESEASES)

(TECHNOLOGY)

OVERVIEW

ARMED EFFECTOR CELLS

PATENTED ENGINEERING OF EXISTING AND NOVEL MONOCLONAL ANTIBODIES ABS AND FC-BASED LIGANDS ENABLES FORMULATION OF PRE-ARMED ALLOGENEIC OR AUTOLOGOUS EFFECTOR CELLS FOR SPECIFIC, STABLE AND PERSISTENT POTENCY IN AN OFF-THE-SHELF FORMAT.

EFFECTOR CELL

ANY EFFECTOR CELL TYPE WITH A NATURAL OR ENGINEERED CD16 RECEPTOR (NK, MACROPHAGES, ETC.) CAN BE ARMED USING CYTEA|BIO‘S ENGINEERED TARGETING ANTIBODIES OR LIGANDS.

FOR EACH EFFECTOR CELL TYPE, ONE CELL POPULATION CAN BE ARMED WITH A WIDE RANGE OF SINGLE OR MULTIPLE TARGETING LIGANDS

+

TARGETING LIGAND

PIN™ PLATFORM EFFECTOR CELLS ARE PRE-ARMED WITH SINGLE OR MULTIPLE MONOCLONAL ANTIBODY(IES) OR Fc CONSTRUCT(S)

PATENTED ENGINEERING (AMINO ACID SUBSTITUTION) OF Fc PART TO ENGENDER STRONG BINDING TO Fc RECEPTOR AND PERMANENTLY ARM CELLS PRIOR TO ADMINISTRATION TO PATIENTS.
CAN BE APPLIED ACROSS FULL LIBRARY OF KNOWN THERAPEUTIC MONOCLONAL ANTIBODIES, NEWLY DISCOVERED MONOCLONAL ANTIBODOESAS WELL AS FC-BASED LIGAND CONSTRUCTS (PEPTIDES, ANTIGENS, RECEPTORS).
SPECIFIC ANTIGENS EXPRESSED BY TUMOR CELLS

=

DRUG PRODUCT

CONSISTS OF CRYOPRESERVED PRE-ARMED EFFECTOR CELLS READY FOR USE.

MANUFACTURING – STRAIGHTFORWARD SELF-ASSEMBLY UPON MIXING OF CELLS AND LIGAND MOLECULES
REGULATORY – STRAIGHTFORWARD. SAME CORE DRUG CHARACTERISTICS AND CMC FOR MULTIPLE UNIQUE PRODUCTS
MODULARITY – EXTENSIVE. EXTENSIVE. RAPID FORMULATION OF NEW CELL THERAPY PRODUCTS FOR ANY IDENTIFIED TARGET HAVING AN AVAILABLE (OR CREATED) LIGAND.